260 related articles for article (PubMed ID: 32581796)
1. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database.
Ruggiero R; Fraenza F; Scavone C; di Mauro G; Piscitelli R; Mascolo A; Ferrajolo C; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Pharmacol; 2020; 11():830. PubMed ID: 32581796
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database.
Nicoletti MM; Crisci E; Cosenza V; Riccardi C; Campitiello MR; Ruggiero D; Berrino PM; Docimo G; Scavone C
Drugs Real World Outcomes; 2024 Mar; 11(1):33-41. PubMed ID: 37907712
[TBL] [Abstract][Full Text] [Related]
4. Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias?
Mascolo A; Sportiello L; Rafaniello C; Donniacuo M; Ruggiero D; Scisciola L; Barbieri M; Rossi F; Paolisso G; Capuano A
Biomed Pharmacother; 2023 Aug; 164():114912. PubMed ID: 37210896
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
Cutroneo PM; Isgrò V; Ientile V; Santarpia M; Ferlazzo G; Fontana A; Carrega P; Matarangolo E; Barnaba S; Spina E; Trifirò G
Br J Clin Pharmacol; 2021 Feb; 87(2):527-541. PubMed ID: 32495965
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
Guo Q; Gao J; Guo H; Xie J; Cheng J
Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study.
Haeuser L; Marchese M; Cone EB; Noldus J; Bayliss G; Kilbridge KL; Trinh QD
Nephrol Dial Transplant; 2022 Jun; 37(7):1310-1316. PubMed ID: 34028534
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management.
Ruggiero R; Di Napoli R; Balzano N; Ruggiero D; Riccardi C; Anatriello A; Cantone A; Sportiello L; Rossi F; Capuano A
Expert Rev Clin Pharmacol; 2023 May; 16(5):423-434. PubMed ID: 37144360
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports.
Khurana A; Dubey H; Arora MK
Curr Drug Saf; 2024 Jan; ():. PubMed ID: 38310553
[TBL] [Abstract][Full Text] [Related]
10. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
[TBL] [Abstract][Full Text] [Related]
11. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
Fan Q; Chen H; Hu Y; Zhao B
Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
[TBL] [Abstract][Full Text] [Related]
13. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
Liang X; Xiao H; Li H; Chen X; Li Y
Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
[TBL] [Abstract][Full Text] [Related]
14. Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data.
Ruggiero R; Stelitano B; Fraenza F; di Mauro G; Scavone C; Sportiello L; Rafaniello C; Di Napoli R; Danesi R; Del Re M; Rossi F; Capuano A
Front Oncol; 2022; 12():824511. PubMed ID: 35372076
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN
Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661
[TBL] [Abstract][Full Text] [Related]
17. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
19. Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy.
Scavone C; Di Mauro C; Ruggiero R; Bernardi FF; Trama U; Aiezza ML; Rafaniello C; Capuano A
Drugs Real World Outcomes; 2020 Mar; 7(1):41-51. PubMed ID: 31848905
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
Ebinama U; Sheshadri A; Anand K; Swaminathan I
J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
